Jasper Therapeutics, Inc.
JSPR
$5.38
-$0.005-0.09%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 5.51M | 5.43M | 4.70M | 4.77M | 3.89M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 25.29M | 19.89M | 15.99M | 15.07M | 17.73M |
Operating Income | -25.29M | -19.89M | -15.99M | -15.07M | -17.73M |
Income Before Tax | -24.32M | -18.64M | -14.58M | -13.73M | -16.58M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -24.32M | -18.64M | -14.58M | -13.73M | -16.58M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -24.32M | -18.64M | -14.58M | -13.73M | -16.58M |
EBIT | -25.29M | -19.89M | -15.99M | -15.07M | -17.73M |
EBITDA | -25.04M | -19.35M | -15.69M | -14.78M | -17.44M |
EPS Basic | -1.62 | -1.24 | -0.97 | -1.03 | -1.50 |
Normalized Basic EPS | -1.01 | -0.78 | -0.61 | -0.64 | -0.94 |
EPS Diluted | -1.62 | -1.24 | -0.97 | -1.03 | -1.50 |
Normalized Diluted EPS | -1.01 | -0.78 | -0.61 | -0.64 | -0.94 |
Average Basic Shares Outstanding | 15.01M | 15.00M | 14.99M | 13.33M | 11.04M |
Average Diluted Shares Outstanding | 15.01M | 15.00M | 14.99M | 13.33M | 11.04M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |